Last updated: February 27, 2026
What is NDC 00904-6994?
NDC 00904-6994 corresponds to the drug Ibrutinib (brand name: Imbruvica). Approved by the FDA for indications including mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström’s macroglobulinemia, and marginal zone lymphoma. It is marketed by Pharmacyclics LLC, AstraZeneca, and partners.
Market Size and Growth Drivers
Current Market Penetration
- In 2022, the U.S. prescription market for Ibrutinib was approximately 350,000 prescriptions, representing a significant portion of the targeted hematological malignancies.
- The global CLL drugs market was valued at approximately USD 5.4 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 8.5% through 2030, driven by increasing diagnoses and new indications.
Key Competitors
| Drug |
Approvals |
Price Range (USD) |
Market Share (2022) |
Indications |
| Ibrutinib |
FDA-approved for 4 indications |
$10,000–$13,000/month |
~55% |
CLL, MCL, WM, ZMT |
| Acalabrutinib |
Approved for CLL/SLL |
$9,500–$12,000/month |
~20% |
CLL/SLL |
| Zanubrutinib |
Approved for MCL, CLL |
$8,700–$11,500/month |
~15% |
MCL, CLL |
Market Trends
- Increasing utilization in second-line therapy.
- Emerging evidence supports off-label use in other B-cell malignancies.
- Increasing prevalence of B-cell malignancies, especially among aging populations.
Price Projections
Current Pricing Structure
- Wholesale Acquisition Cost (WAC): approximately $12,200/month as of Q1 2023.
- Actual patient out-of-pocket costs vary depending on insurance and discounts, generally around $500–$2,000/month.
Factors Influencing Future Prices
- Patent expiry: Patents expire in 2027, opening the market to biosimilars and generics.
- Patent litigation: Ongoing disputes may delay biosimilar entry.
- Market competition: Entry of generic and biosimilar competitors could reduce prices by 50–75% within 2-3 years post-patent expiry.
- Manufacturer pricing strategies: Price reductions to maintain market share before biosimilar entry.
Price Forecast (2023–2030)
| Year |
Estimated Price Range (USD/month) |
Notes |
| 2023 |
$12,000–$13,000 |
Current prices sustained. |
| 2024 |
$11,500–$12,800 |
Slight decreases expected as biosimilar competition approaches. |
| 2026 |
$10,500–$11,500 |
Prices decline as biosimilar market entry nears, pre-launch discounts begin. |
| 2027 |
$5,000–$8,000 |
Biosimilar entry expected, prices potentially cut in half or more. |
| 2028–2030 |
$2,500–$4,000 |
Further reductions as biosimilars dominate, with possible price stabilization. |
Impact of Biosimilar Entry
- Biosimilars likely to capture 60–80% of prescriber share within the first 2 years.
- Discounted biosimilar prices are projected to be 60–80% lower than the branded version.
- The speed of adoption hinges on regulatory approvals, payer policies, and physician acceptance.
Regulatory and Policy Influences
- The U.S. FDA has approved certain biosimilar versions of Ibrutinib; generic versions are not yet available.
- Payer policies favor biosimilars due to lower costs, incentivizing switchovers.
- Non-price factors, such as efficacy and safety profiles, will impact market shares of biosimilars.
Market Entry Timelines
- Biosimilar approvals expected post-2026.
- Patent litigation and legal challenges could delay biosimilar launches until 2028 or later.
- Regional variation: Europe may see earlier biosimilar availability due to different regulatory timelines.
Strategic Considerations for Stakeholders
- Current high prices support significant margins; early biosimilar entrants must price competitively to gain market share.
- Payers seek cost-effective alternatives; negotiations will be critical.
- R&D investments in combination therapies could diversify revenue streams beyond monotherapy.
Key Takeaways
- NDC 00904-6994 (Ibrutinib) is a highly established therapy with a market valued at several billion USD globally.
- The market is expanding, with increasing approvals and indications.
- Prices are forecasted to decline sharply post-2027, influenced by biosimilar entries.
- Market share dynamics depend heavily on regulatory approvals, payer policies, and physician adoption.
- Long-term price stabilization is likely in the $2,500–$4,000/month range once biosimilars dominate.
FAQ
Q1: When will biosimilars for Ibrutinib typically enter the market?
A1: Biosimilar entry is expected around 2027–2028, after patent expiration and regulatory approvals.
Q2: How much could prices decrease after biosimilar entry?
A2: Prices could decline by 60–80%, potentially reducing monthly costs to $2,500–$4,000.
Q3: What factors could delay biosimilar market entry?
A3: Patent litigation, regulatory hurdles, and legal disputes can delay biosimilar approval and launch.
Q4: Which competitors pose the greatest threat to Ibrutinib's market share?
A4: Acalabrutinib and Zanubrutinib are primary competitors, holding approximately 35% combined market share.
Q5: How does regional variation affect biosimilar availability?
A5: Europe generally approves biosimilars earlier; the U.S. typically sees delays due to regulatory and patent issues.
References
[1] U.S. Food and Drug Administration. (2022). Imbruvica (Ibrutinib) prescribing information.
[2] MarketWatch. (2023). Hematological malignancies drug market report.
[3] EvaluatePharma. (2022). Oncology drug pipeline and pricing report.
[4] IQVIA. (2022). U.S. prescription drug market analysis.
[5] FDA. (2022). Biosimilar approval and regulation guidelines.
